Ignite Creation Date:
2025-12-24 @ 7:55 PM
Ignite Modification Date:
2025-12-30 @ 12:06 PM
Study NCT ID:
NCT05727904
Status:
RECRUITING
Last Update Posted:
2025-07-08
First Post:
2023-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Sponsor:
Iovance Biotherapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-30
Start Date Type:
ACTUAL
Primary Completion Date:
2028-03-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-03-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-06
First Submit QC Date:
None
Study First Post Date:
2023-02-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-07
Last Update Post Date:
2025-07-08
Last Update Post Date Type:
ACTUAL